Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
TD Cowen Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH)
June 30, 2025 1:09 PM EDTTD Cowen analyst Stacy Ku reiterated a Buy rating and $11.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH).
The analyst comments "Phase I healthy volunteer SAD data for aritinercept/AUR200 (BAFF/April inhibitor) appear to be matching other competitive/BIC programs in development. Specifically, a single dose of aritinercept demonstrated max reduction from baseline of 20% for IgG, 48% for IgA, and 55% IgM at 225mg dose, and effects appear saturated at higher doses (225/300mg; details below). The PK/PD profile supports monthly subcutaneous dosing (half-life 6-8 days) - with... More
Aurinia Pharmaceuticals (AUPH) Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
June 30, 2025 6:01 AM EDTAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects.
Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade 3 adverse... More
